Please select the option that best describes you:
Topics:
Radiation Oncology • Gastrointestinal Cancers
If a patient with initially borderline resectable pancreatic cancer receives neoadjuvant CHT followed by CRT and is ultimately deemed unresectable, do you consider an RT boost?
Would you manage this differently based on radiation dose (36/15 fx vs 50.4/28 fx)?